Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- FDA authorizes investigational new drug application for recombinant human C1 inhibitor in kidney transplantation
- Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that the US Food and Drug Administration FDA has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection AMR in kidney transplantation. Dr. Hans Sollinger of the University of...
- Research articles 2008-09-03
- Pharming to Present at UBS Global Life Sciences Conference
- Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) today announced that Pharming will present at the UBS Global Life Sciences (September 24-27, 2007) in New York.
- Research articles 2007-09-19
- PHARMING TO PRESENT AT UBS GLOBAL LIFE SCIENCES CONFERENCE
- Leiden, The Netherlands, September 21, 2006. Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) announced today that Dr. Francis Pinto, Chief Executive Officer of Pharming will present at the UBS Global Life Sciences Conference...
- Research articles 2006-09-21
- Trading for a high.
- Byline: Carolyn Banta Aug 03, 2005 (Time Australia - ABIX via COMTEX) -- There is a growing trend in the US for teenage drug abusers to use prescription ...
- Research articles 2005-08-03
- Shred reckoning.(UPGRADE: Abusive Lab Test)(Brief Article)
- THE RISE OF INTERNET SCAMS such as phishing and now pharming (see page 24) has given identity thieves the luxury of working from home, but a great deal of stolen information still comes from personal documents. The Federal Trade Commission recommends shredding receipts, credit card applications,...
- Research articles 2005-08-01
- The Threats of Pharming Unveiled in Mirapoint's Analyst Corner
- SUNNYVALE, Calif. -- The Radicati Group Examines the Threats of Pharming in the Analyst Corner April Edition
- Research articles 2006-04-19
- PHARMING RECEIVES ORPHAN DRUG DESIGNATION FOR RECOMBINANT FIBRINOGEN FROM FDA
- PHARMACEUTICAL DEVELOPMENT For FiBRINOGEN DEFICIENCIEs Initiated
- Research articles 2007-10-11
- PHARMING HIGHLIGHTS RESEARCH INNOVATION AND NEW GROWTH ERA AT UBS CONFERENCE
- Leiden, The Netherlands, September 25, 2006. Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) presented today on its value creation and research innovation at the UBS Global Life Sciences Conference in New York.
- Research articles 2006-09-25
- Pharming: the food industry says genetically modified food is perfectly safe; consumers, environmentalists, and many others aren't so sure. (Food - GM Food).(Statistical Data Included)
- Traditional plant genetics swaps genes between similar species, so the process is more like natural selection. Genetic engineering allows genes from any plant or organism to be inserted into any other plant or organism, by-passing natural reproductive barriers between species. For example, fish genes have been...
- Research articles 2002-03-01
- PHARMING TO PRESENT AT ING HEALTHCARE CONFERENCE
- Leiden, The Netherlands, December 1, 2005. Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that the Company will present at the 5th Annual ING European Healthcare Conference (December 6-7, 2005) in London.
- Research articles 2005-12-01
- Pharming Healthcare to Open Blacksburg, Va., Dairy Drug Plants.
- Knight Ridder/Tribune Business News Jun. 30 -- RICHMOND, Va. -- A Dutch company that develops human medicines using animals' milk is coming to Craig County and Blacksburg, bringing 88 jobs and $37 million in investments with it, state government officials confirmed Monday. ...
- Research articles 1999-07-01
- Pharming Group N.V. Reports Half year Results 2000, Revenues up 75% — Pharming strengthened partnership with Genzyme
- Business Editors LEIDEN, The Netherlands--BUSINESS WIRE--Aug. 1, 2000--Pharming Group N.V. (EASDAQ: PHAR / AEX: PHAR) announced financial interim results for its first half-year ended June 30, 2000. Financial Highlights -- Total revenues increased 75% to...
- Research articles 2000-08-01
- PHARMING RECIEVES ORPHAN PRODUCT GRANT FROM US FDA FOR RHUCIN(R)
- Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) announced today that it has received a grant from the US FDA's Office of Orphan Products Development OPD for the clinical development...
- Research articles 2006-10-06
- PHARMING RECIEVES ORPHAN DRUG DESIGNATIONS FOR RHC1INH FROM US FDA
- Leiden, The Netherlands, June 14, 2006. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) announced today it has received orphan drug designations for recombinant human C1 inhibitor (rhC1INH) from the Food and Drug Administration FDA. The Company has obtained...
- Research articles 2006-06-14
- PHARMING RECEIVES FAST TRACK DESIGNATION FROM US FDA FOR RECOMBINANT HUMAN C1 INHIBITOR
- Leiden, The Netherlands, July 28, 2006. Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) announced today that it has received a Fast Track designation on recombinant human C1 inhibitor (rhC1INH) for the treatment of hereditary angioedema HAE from the US Food and Drug...
- Research articles 2006-07-28
- Media Alert: Check Point Preemptively Protects Against New Pharming Attack
- Check Point SmartDefense subscribers immune to BIND DNS server threat
- Research articles 2007-09-19
- GENZYME Corp.(acquires assets of Pharming NV)(Brief Article)
- GENZYME Corp. has acquired certain assets of Pharming NV, a Belgium-based Pharming Group subsidiary operating under a court supervised receivership, including a 70,000 square foot cGMP protein manufacturing unit being built, and a transgenic human GENZYME Corp. has acquired certain assets of Pharming...
- Research articles 2001-11-05
- Gene Pharming Europe acquires casein promoter patents from Biogen
- MOUNTAIN VIEW, Calif.--BUSINESS WIRE--Jan. 24, 1995--GenPharm International's European affiliate, Gene Pharming Europe B.V., (Leiden, The Netherlands) announced Tuesday the acquisition from Biogen Inc. (Cambridge, Mass.) of U.S. patent No. 4,873,316 and corresponding U.S. and international patent filings.
- Research articles 1995-01-24
- Gene Pharming Europe and Genzyme Transgenics cross-license key patent rights
- MOUNTAIN VIEW, Calif.--BUSINESS WIRE---Jan. 24, 1995--GenPharm International's European affiliate, Gene Pharming Europe B.V., Leiden, The Netherlands, and Genzyme Transgenics Corp. (NASDAQ:GZTC), Framingham, Mass., Tuesday announced that they cross-licensed certain fundamental patent rights.
- Research articles 1995-01-24
- Teros Reveals Expanded Anti-Fraud Features in Leading Web Application Gateway; New Appliance Detects and Prevents Deep-Linking and Site Scraping, Greatly Reducing the Effectiveness of Phishing and Pharming Attacks
- SUNNYVALE, Calif. -- Teros, the global leader in Web application firewalls, today revealed version 5.2 of the Teros 100 and 200 Web Application Gateways, enhanced to protect against online fraud including phishing. New enhancements include expanded anti-fraud features that disrupt multiple stages of the online fraud life cycle. The solution...
- Research articles 2005-09-19
- << Previous
- page 1 of 2
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
